Get the Stockscreener App
7.075
0.00%
0.015
Capricor Therapeutics Inc stock is traded at $7.075, with a volume of 61,409.
It is up +0.00% in the last 24 hours and up +11.48% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$7.09
Open:
$7.13
24h Volume:
61,409
Relative Volume:
0.03
Market Cap:
$323.22M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-8.5241
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-9.22%
1M Performance:
+11.48%
6M Performance:
-23.68%
1Y Performance:
-60.10%
1-Day Range:
$7.04
$7.1577
1-Week Range:
$7.04
$7.8199
52-Week Range:
$5.68
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.07 | 324.13M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics : Investor PresentationOctober 2025 - MarketScreener
How analysts rate Capricor Therapeutics Inc. stock today2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
Historical volatility pattern of Capricor Therapeutics Inc. visualizedGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Can trapped investors hope for a rebound in Capricor Therapeutics Inc.New Guidance & Long-Term Safe Investment Plans - newser.com
Heatmap analysis for Capricor Therapeutics Inc. and competitorsInsider Selling & Real-Time Stock Movement Alerts - newser.com
Is a relief rally coming for Capricor Therapeutics Inc. holdersWeekly Risk Summary & Daily Profit Focused Screening - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025Weekly Loss Report & Community Driven Trade Alerts - newser.com
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Capricor Therapeutics Inc Stock Analysis and ForecastMomentum Stock Picks & Minimal Investment Capital Gains - earlytimes.in
What drives Capricor Therapeutics Inc 4LN2 stock priceMarket Correction Analysis & Affordable Market Insights - earlytimes.in
Will Capricor Therapeutics Inc. stock see PE expansionInsider Buying & Free Verified High Yield Trade Plans - newser.com
Volume spikes in Capricor Therapeutics Inc. stock – what they meanWeekly Market Report & Daily Technical Forecast Reports - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock profit from AI boom2025 Market Overview & Growth Focused Investment Plans - newser.com
Is Capricor Therapeutics Inc. stock resilient to inflationJuly 2025 Technicals & Community Supported Trade Ideas - newser.com
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval - streetwisereports.com
How Capricor Therapeutics Inc. stock reacts to job market dataMarket Activity Summary & AI Optimized Trading Strategy Guides - newser.com
Capricor Therapeutics Inc. recovery potential after sell off2025 Sector Review & Safe Entry Zone Tips - newser.com
Published on: 2025-10-05 04:39:29 - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a good hedge against inflation2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
User - FinancialContent
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewswire
There's Reason For Concern Over Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Massive 26% Price Jump - 富途牛牛
Head to Head Review: Baxter International (NYSE:BAX) and Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Largest borrow rate increases among liquid names - TipRanks
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy - streetwisereports.com
Biotech Battles FDA, Target Price Shows Potential 90% Gains - streetwisereports.com
Hope On The Horizon As Capricor's HOPE-3 Trial For Duchenne Muscular Dystrophy Nears Data Readout - RTTNews
Is ICICI Prudential Asset Management Co Ltd Stock a Strong Buy According to Wall StreetGlobal Trade Effects & Free Stock Trading Workshops - earlytimes.in
What analysts say about Capricor Therapeutics Inc stockRetail Trading Trends & Low Cost Stock Picks - earlytimes.in
Can Sagardeep Alloys Limited Deliver DoubleDigit Returns in the Next YearStock Liquidity Analysis & Free Stop-Loss Planning for Your Portfolio - earlytimes.in
Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 (NASDAQ:CAPR) - Seeking Alpha
Why analysts maintain buy rating on Capricor Therapeutics Inc. (4LN2) stock2025 Top Gainers & Trade Opportunity Analysis - newser.com
Published on: 2025-09-29 09:30:46 - newser.com
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):